Business Wire

Enapter Opens Serial Fabrication Facility for Modular Hydrogen Electrolysers

Share

Enapter, a manufacturer of modular hydrogen electrolysers, announced today the unveiling of its new serial fabrication facility in Pisa. The revamped manufacturing process will increase Enapter’s production capacity eightfold and reduce electrolyser costs by more than 20 percent. These improvements can make onsite hydrogen generation an affordable reality for a multitude of applications worldwide, including energy storage, backup power, power-to-heat, industrial hydrogen production and hydrogen-based mobility.

Hydrogen generation has the potential to play a key role in the clean energy transition but has been limited by cost and scalability. Enapter’s EL 2.0 electrolyser addresses these challenges through its patented Anion Exchange Membrane (AEM) technology. With a simple balance of plant and no noble metals needed, Enapter’s AEM reduces costs and increases lifetime performance of hydrogen generation. Serial fabrication allows Enapter to deploy the current EL 2.0 hydrogen generator to an even larger customer base while creating capacity for the forthcoming EL 2.1 product.

“This new facility marks a major milestone for us,” said Sebastian-Justus Schmidt, Chairman of Enapter. “Our mission is to make green hydrogen generation cheaper than fossil fuels. As we look ahead, this process will help us mass produce our electrolysers for projects around the world. This is a crucial step into making hydrogen electrolysers into a standardized, valuable commodity that can compete with outdated legacy energy sources.”

As a stackable system, facilities of all sizes use the EL 2.0. Current applications generating hydrogen from Enapter electrolysers include island mini grids, seasonal energy storage in the Alps, residential heating in the Netherlands, renewable methane production in Australia, nitrogen purification in Portugal, fuel cell drone refueling in China and many more. To learn more about Enapter’s solutions, visit: https://enapter.com

About Enapter

Enapter manufactures highly efficient, modular hydrogen generators using Anion Exchange Membrane electrolysis. Its core technology has a 10-year proven track record. It is the foundation for the unique low-cost, compact electrolyser. The EL 2.0 is fully stackable and easy to integrate with Enapter’s Energy Management System. Enapter systems are used internationally in industries like telecommunications, mobility, and energy. The team combines electrochemical and IT expertise to drive the Hydrogen Economy in hardware and software. Enapter has offices in Berlin, Pisa, Bangkok and St Petersburg. https://www.enapter.com

Contact information

Antenna
Kalena Gravina
enapter@antennagroup.com
201-465-8013

Enapter
Vaitea Cowan
vaitea@enapter.com
+39 050 644 281

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Empirix Encrypted OTT Video Assurance and Reporting Solution Provides Visibility Into Content Delivery Network Performance22.10.2019 07:00:00 CESTPress release

Empirix Inc., a premier global provider of voice, data, mobility, IoT and multimedia service assurance solutions, today announced the availability of a new assurance solution for encrypted OTT video traffic. Empirix’s new solution simplifies workflow and drill down for faster root cause analysis of OTT video related issues across locations, devices and networks, including content delivery networks (CDN). The new OTT video package includes the reporting tool Diagnostix Operational Reports (DOR) which provides ubiquitous visibility into encrypted video traffic via a series of out-of-the-box, pre-defined reports that correlate video-related QoS parameters to deliver immediate value without custom development. With OTT video use significantly impacting service quality, CSPs must be able to identify and resolve video-related performance issues. However, encrypted content and lack of visibility into third-party content delivery networks (CDN) is making it hard for CSPs to not only identify a

Yunnan, A Must-Go Place Making Young People Enchanted22.10.2019 06:48:00 CESTPress release

In Yunnan, such a 394,100-square-kilometer vast land, there is full of magic and romance. From valleys with an altitude of 76 meters to peaks with an altitude of 6,740 meters, this land encompasses all kinds of spectacular landscape, such as numerous mountains and surging rivers. There are last paradises for wild animals and miraculous plants growing for thousands of years hidden in warm zones, frigid zones, rain forests, meadow, rocks and peaks. Once you get here and see these amazing and magnificent mountains and rivers, you will never turn your eyes elsewhere. “My Favorite Scenic Areas in Yunnan” Five Must-see Scenic Areas The Old Town of Lijiang Chongsheng Temple and Three-Pagoda Culture Tourist Area, Dali Xishuangbanna Primeval Forest Park Co., Ltd. Yuanmou People Museum, Chuxiong Heshun Ancient Town, Tengchong “My Favorite Scenic Areas in Yunnan” Five Scenic Areas Making You Come Back Jade Dragon Snow Mountain Scenic Area, Lijiang Yunfeng Mountain Scenic Area, Tengchong China Pu’

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study22.10.2019 05:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen specific immune tolerance platform, TAK-101 is a potential first-in-class treatment targeting the aberrant immune response in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage in the small intestine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005739/en/ Results of a randomized, double-blind, placebo-controlled clinical trial to assess the markers of potential efficacy and safety of the investigational medicine in 34 adults with proven celiac disease was presented today as a late-breaking abstract at UEG Wee

Crocs Gets “Lit” This #CrocDay22.10.2019 04:01:00 CESTPress release

Crocs, Inc. (NASDAQ: CROX) a global leader in innovative, casual footwear for women, men and children, continues its annual Croctober celebration by partnering with premier streetwear brand Pizzaslime to deliver their latest, limited-edition, glow-in-the-dark version of the Classic Clog for Croc Day on Wednesday, October 23rd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005886/en/ This year's limited edition #CrocDay Classic Clog will come fully loaded with a curated assortment of custom #CROCDAYISLIT Jibbitz™ charms — some of which glow! ​(Photo: Business Wire) National Croc Day was adopted by brand fans as a way to celebrate all things Crocs with the shared hashtag #CrocDay. Last year’s limited-edition Croc Day shoe sold out within hours. To commemorate this year’s event, the shoe will arrive fully-loaded with a curated assortment of custom, glow-in-the-dark #CROC DAY IS LIT Jibbitz™ charms – the first of their ki

Logitech Delivers Solid Second Quarter Growth and Profitability22.10.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2020. Q2 sales were $720 million, up 4 percent in US dollars and 6 percent in constant currency, compared to Q2 of the prior year. Q2 GAAP operating income grew 4 percent to $68 million, compared to $65 million in the same quarter a year ago. Q2 GAAP earnings per share (EPS) grew 13 percent to $0.43, compared to $0.38 in the same quarter a year ago. Q2 non-GAAP operating income grew 6 percent to $89 million, compared to $85 million in the same quarter a year ago. Q2 non-GAAP EPS grew 2 percent to $0.50, compared to $0.49 in the same quarter a year ago. Cash flow from operations was $107 million, compared to $85 million in the same period a year ago. “Our solid Q2 demonstrates Logitech’s resilience as we continue to execute on our strategy,” said Bracken Darrell, Logitech president and chief executive officer. “This quarter, we delivered record sales in Video Collabo

Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)21.10.2019 18:27:00 CESTPress release

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ® (ivacaftor) for eligible patients in Spain living with cystic fibrosis (CF). Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO. Ludovic Fenaux, Senior Vice President, Vertex International, commented, “Today’s announcement means ORKAMBI and SYMKEVI can be prescribed from the first of Nov